engleski

PEPTIDE BASED SYNTHETIC VACCINES: FROM EPITOPE TO ADJUVANTS

Peptide vaccines represent an alternative to conventional vaccines which are trying to address issues of possible vaccine side effects related to vaccination with a heterogeneous multicomponent preparation of classical vaccines.[1] Synthetic peptide vaccines are usually composed of 20–30 amino acids comprising the specific epitope of an antigen related to infectious and/or chronic diseases including cancers. Their advantages over other types of vaccines such as conventional vaccines and newly developed DNA vaccines include easy synthesis at a low cost, increased stability, and relative safety generally demonstrated in numerous preclinical and clinical studies. In addition, peptide vaccines have no limitation in target diseases, from virus infection to Alzheimer disease, cancer and even allergy. Despite high expectations, the peptide-based vaccines that have been explored in the clinic have so far had limited therapeutic activity. Some of limitations include epitope identification and selection of most relevant epitopes, lack of immunogenicity, immune evasion and clinical evaluation.[2] The lecture attempts to summarize the most significant challenges in peptide vaccine development focusing on the innovative approach overcoming those limitations, in particular in vaccine formulations with appropriate adjuvants.

Peptide vaccines, adjuvants, epitopes, vaccine formulations

nije evidentirano